Sunday May 31, 2020

Cancer drug patent denied by court

Gleevec was Novartis’s best-selling product last year with sales of $4.7 billion.

1st April, 2013
Novartis has argued that Gleevec deserves patent protection.

India’s Supreme Court has denied Novartis AG’s request for patent protection for its Gleevec cancer treatment, allowing the nation’s generic drugmakers to continue to sell copies of the drug at a lower price.

In a decision watched by non-profit groups seeking to expand access to medicines and drugmakers concerned about India’s position on intellectual property, the court upheld regulatory rulings dating to 2006 that the drug wasn’t sufficiently innovative...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The best writing and and the biggest stories of 2019 from the Business Post

Richie Oakley | 5 months ago

Denis O’Brien is back in court, residents continue to fight the Council on halting site and a row surfaces in government over rent control proposals

Leanna Byrne | 4 years ago